Showing results (1-10 of 5) with videos related to
Sort By:
Pageof 1
British Journal of Haematology|October 10, 2025
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphomaRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.Clinical Lymphoma, Myeloma & Leukemia|December 28, 2020
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell LymphomaSolomon A Graf, Ryan D Cassaday, Karolyn Morris, et al.Blood Advances|December 15, 2022
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomasRyan C Lynch, Christina Poh, Chaitra S Ujjani, et al.The Lancet. Haematology|July 30, 2021
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 studyRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.Cancer Immunology Research|February 1, 2018
Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single CenterAaron Lisberg, D Andrew Tucker, Jonathan W Goldman, et al.Pageof 1